Dr. Yadav on the Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma
September 10th 2019Ghanshyam Yadav, MD, discusses research surrounding the combination of the PARP inhibitor olaparib and the pan-HER TKI neratinib, which proved to be highly synergistic and had significant activity in preclinical models of HER2-positive uterine serous carcinoma.
Read More
Dr. Yadav on Olaparib/Neratinib in HER2-Overexpressing Uterine Serous Carcinoma
March 29th 2019Ghanshyam Yadav, MD, first-year resident, Baylor College of Medicine, discusses the combination of olaparib (Lynparza) and neratinib (Nerlyx) in patients with HER2-overexpressing uterine serous carcinoma.
Read More